摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

trans-tert-butyl 5-oxo-3,3a,4,5-tetrahydro-1H-pyrrolo[3,4-c]isoquinoline-2(9bH)-carboxylate

中文名称
——
中文别名
——
英文名称
trans-tert-butyl 5-oxo-3,3a,4,5-tetrahydro-1H-pyrrolo[3,4-c]isoquinoline-2(9bH)-carboxylate
英文别名
tert-butyl (3aS,9bR)-5-oxo-3,3a,4,9b-tetrahydro-1H-pyrrolo[3,4-c]isoquinoline-2-carboxylate
trans-tert-butyl 5-oxo-3,3a,4,5-tetrahydro-1H-pyrrolo[3,4-c]isoquinoline-2(9bH)-carboxylate化学式
CAS
——
化学式
C16H20N2O3
mdl
——
分子量
288.346
InChiKey
LJINFLYUSOVTHB-QWHCGFSZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    58.6
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Pyrrolo(oxo)isoquinolines as 5HT ligands
    申请人:Fevig M. John
    公开号:US20060014777A1
    公开(公告)日:2006-01-19
    The present application describes compounds according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I or pharmaceutically acceptable salt forms thereof, wherein A, B, D, E, m, n, R 3 , R 7 , R 8 , R 9 , R 10 , R 11 and X are described herein.
    本申请描述了根据式I的化合物,包括至少一种根据式I的化合物和可选地至少一种额外的治疗剂的药物组合物,以及治疗与调节5-羟色胺受体相关的各种疾病、症状和紊乱的方法,例如:代谢性疾病,包括但不限于肥胖症、糖尿病、糖尿病并发症、动脉粥样硬化、糖耐量受损和血脂异常;中枢神经系统疾病,包括但不限于焦虑、抑郁症、强迫症、恐慌症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症;头痛;偏头痛;以及使用根据式I的化合物或其药用盐形式治疗胃肠道紊乱,其中A、B、D、E、m、n、R3、R7、R8、R9、R10、R11和X在此处描述。
  • US7572805B2
    申请人:——
    公开号:US7572805B2
    公开(公告)日:2009-08-11
  • Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists
    作者:John M. Fevig、Jianxin Feng、Karen A. Rossi、Keith J. Miller、Ginger Wu、Chen-Pin Hung、Thao Ung、Sarah E. Malmstrom、Ge Zhang、William J. Keim、Mary Jane Cullen、Kenneth W. Rohrbach、Qinling Qu、Jinping Gan、Mary Ann Pelleymounter、Jeffrey A. Robl
    DOI:10.1016/j.bmcl.2012.10.091
    日期:2013.1
    A series of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones is described, several examples of which exhibit potent 5-HT2C agonism with excellent selectivity over the closely related 5-HT2A and 5-HT2B receptors. Compounds such as 38 and 44 were shown to be effective in reducing food intake in an acute rat feeding model. (C) 2012 Elsevier Ltd. All rights reserved.
查看更多